PriceTargets.com logo

Alzamend Neuro - ALZN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.72 As of 04/17/2024 01:00 AM ET
▼ -0.04 (-5.23%)

This chart shows the closing price for ALZN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alzamend Neuro Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALZN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALZN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Alzamend Neuro in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.72.

This chart shows the closing price for ALZN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Alzamend Neuro. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2023Maxim GroupInitiated CoverageBuy$22.50Low
11/5/2021Univest SecInitiated CoverageBuy$225.00High
10/1/2021Ascendiant Capital MarketsInitiated CoverageBuy$120.00Low
(Data available from 4/18/2019 forward)

News Sentiment Rating

-0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/21/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Alzamend Neuro logo
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Read More

Today's Range

Now: $0.72
Low: $0.70
High: $0.77

50 Day Range

MA: $0.95
Low: $0.72
High: $1.20

52 Week Range

Now: $0.72
Low: $0.70
High: $11.91

Volume

58,033 shs

Average Volume

48,419 shs

Market Capitalization

$4.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Alzamend Neuro?

The following Wall Street sell-side analysts have issued stock ratings on Alzamend Neuro in the last twelve months:
View the latest analyst ratings for ALZN.

What is the current price target for Alzamend Neuro?

0 Wall Street analysts have set twelve-month price targets for Alzamend Neuro in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Alzamend Neuro in the next year.
View the latest price targets for ALZN.

What is the current consensus analyst rating for Alzamend Neuro?

Alzamend Neuro currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ALZN.

What other companies compete with Alzamend Neuro?

Other companies that are similar to Alzamend Neuro include Exicure, Seelos Therapeutics, Kineta, Oragenics and Sonnet BioTherapeutics. Learn More about companies similar to Alzamend Neuro.

How do I contact Alzamend Neuro's investor relations team?

The company's listed phone number is 844-722-6303. The official website for Alzamend Neuro is www.alzamend.com. Learn More about contacing Alzamend Neuro investor relations.